

14 March 2022



Regulatory press release

## Enzymatica announces outcome of new rights issue

**NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW.**

**The Board of Directors for Enzymatica ("Enzymatica" or "Company") today announces the outcome of the new rights issue with preferential rights for existing shareholders that was published on 16 February 2024 (the "Rights issue"). The Rights issue was fully subscribed, and the Company will receive proceeds amounting to about SEK 27.4 million before issue costs. The Rights issue was subscribed for 72.7 percent with subscription rights and 7.9 percent without subscription rights. The remaining part of the Rights issue was subscribed for through guarantee commitments by the Company's three largest owners through fully or partly owned companies, as well as the Chairman of the Board and the CEO.**

On 13 March 2024, the subscription period for the Rights issue ended. The final outcome shows that the Rights issue was fully subscribed, whereof 72.7 percent were subscribed for with subscription rights and 7.9 percent without subscription rights. The remaining part, corresponding to 19.4 percent, was subscribed for by the Company's three largest owners, as well as the Company's Chairman of the Board and CEO, according to guarantee commitments. The subscription rate of the new rights issue was SEK 3 per share and the Company will receive proceeds amounting to about SEK 27.4 million before issue costs.

"The rights issue secures working capital for the business and creates a stable basis for negotiations with stakeholders regarding expansion in existing and new markets. During the subscription period, the very positive news came that ColdZyme was one of the first cold and flu products to be certified according to the EU regulation MDR. This means long-term positive effects for our sales", said CEO Claus Egstrand.

By the Rights issue the share capital will increase by SEK 365,015.32 to SEK 6,935,291.29. The total number of shares in the Company will increase from 164,256,840 to 173,382,220.

The last day for trading in paid-up subscribed shares (BTA) on Nasdaq First North Growth Market is expected to be 29 March 2024. The new shares are expected to be traded on Nasdaq First North Growth Market on or about 4 April 2024. The above is the final outcome of the Rights issue, thus no further press releases about the outcome of the Rights issue will be issued.

### **Adviser**

Hagberg & Aneborn Fondkommission AB is Enzymatica's financial adviser in connection with the rights issue. Setterwalls Advokatbyrå is the Company's legal adviser in connection with the rights issue.

For more information, please contact:

Claus Egstrand, CEO, Enzymatica AB  
Phone: +44 7780 22 8385 | Email: [claus.egstrand@enzymatica.com](mailto:claus.egstrand@enzymatica.com)

Stefan Olsson, Communication Manager, Enzymatica AB  
Phone: +46 708 55 11 85 | Email: [stefan.olsson@enzymatica.com](mailto:stefan.olsson@enzymatica.com)



**Enzymatica**  
THE SCIENCE THAT PROTECTS

*Important information*

The information in this press release does not constitute an offer to acquire, subscribe, or otherwise trade in shares or other securities in Enzymatica. The invitation to the concerned persons to subscribe for shares in the Company will only be made through the Information Memorandum that is available on the Company's website (the "Information Memorandum").

This Information Memorandum does not constitute a prospectus as defined in the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council ("Prospectus Regulation") and has neither been reviewed, registered, nor approved by the Swedish Financial Supervisory Authority or any other authority. The new issuance is exempt from prospectus requirements in accordance with Article 3(2) of the Prospectus Regulation and Chapter 2, Section 1 of the Act (2019:414) with complementary provisions to the EU Prospectus Regulation because the Company has not carried out any other offerings of securities to the public during the previous twelve months and the amount offered by the Company to the public in the new issuance is below 2.5 million euro.

No action has been taken and no action will be taken by Enzymatica to permit an offer to the public in any jurisdictions other than Sweden. This press release may not be released, published or distributed, directly or indirectly, in or into Australia, Belarus, Russia, Hong Kong, Japan, Canada, New Zealand, South Africa, South Korea, Switzerland, Singapore, the United States of America, or any other jurisdiction where such action is subject to legal restrictions, or would require a prospectus, registration, or other measures beyond those required by Swedish law, and the new issuance is not directed to persons resident in any of these or other countries, where participation by such persons would require measures other than those required by Swedish law. The information in this press release may not be forwarded or reproduced in a manner that conflicts with restrictions or would entail requirements beyond those of Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation. New shares subscribed for in the new issuance have not been and will not be registered under the United States Securities Act of 1933, as amended ("Securities Act"), and may not be offered, subscribed, utilized, pledged, sold, resold, delivered, or transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from the registration requirements of the Securities Act.